JP2024504471A5 - - Google Patents

Info

Publication number
JP2024504471A5
JP2024504471A5 JP2023545975A JP2023545975A JP2024504471A5 JP 2024504471 A5 JP2024504471 A5 JP 2024504471A5 JP 2023545975 A JP2023545975 A JP 2023545975A JP 2023545975 A JP2023545975 A JP 2023545975A JP 2024504471 A5 JP2024504471 A5 JP 2024504471A5
Authority
JP
Japan
Prior art keywords
sequence
seq
sequence number
amino acid
multispecific antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023545975A
Other languages
English (en)
Japanese (ja)
Other versions
JP7858665B2 (ja
JP2024504471A (ja
Filing date
Publication date
Priority claimed from PCT/EP2021/087618 external-priority patent/WO2022136693A1/en
Application filed filed Critical
Priority claimed from PCT/EP2022/052425 external-priority patent/WO2022167460A1/en
Publication of JP2024504471A publication Critical patent/JP2024504471A/ja
Publication of JP2024504471A5 publication Critical patent/JP2024504471A5/ja
Application granted granted Critical
Publication of JP7858665B2 publication Critical patent/JP7858665B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023545975A 2021-02-02 2022-02-02 Ror1およびcd3に対する特異性を有する多重特異性抗体 Active JP7858665B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21154786.4 2021-02-02
EP21154786 2021-02-02
PCT/EP2021/087618 WO2022136693A1 (en) 2020-12-23 2021-12-23 Antibody variable domains and antibodies having decreased immunogenicity
EPPCT/EP2021/087618 2021-12-23
PCT/EP2022/052425 WO2022167460A1 (en) 2021-02-02 2022-02-02 Multispecific antibodies having specificity for ror1 and cd3

Publications (3)

Publication Number Publication Date
JP2024504471A JP2024504471A (ja) 2024-01-31
JP2024504471A5 true JP2024504471A5 (cg-RX-API-DMAC7.html) 2025-02-12
JP7858665B2 JP7858665B2 (ja) 2026-05-14

Family

ID=80682356

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023545975A Active JP7858665B2 (ja) 2021-02-02 2022-02-02 Ror1およびcd3に対する特異性を有する多重特異性抗体

Country Status (11)

Country Link
US (1) US20240392003A1 (cg-RX-API-DMAC7.html)
EP (1) EP4288451A1 (cg-RX-API-DMAC7.html)
JP (1) JP7858665B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230166075A (cg-RX-API-DMAC7.html)
AU (1) AU2022215847A1 (cg-RX-API-DMAC7.html)
CA (1) CA3208781A1 (cg-RX-API-DMAC7.html)
IL (1) IL304403A (cg-RX-API-DMAC7.html)
MX (1) MX2023009022A (cg-RX-API-DMAC7.html)
PE (1) PE20250740A1 (cg-RX-API-DMAC7.html)
TW (1) TW202248211A (cg-RX-API-DMAC7.html)
WO (1) WO2022167460A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3816185A1 (en) * 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
JP2024540099A (ja) 2021-10-28 2024-10-31 ライエル・イミュノファーマ・インコーポレイテッド Ror1結合タンパク質を発現する細胞を培養する方法
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2025026204A1 (en) * 2023-07-28 2025-02-06 Cstone Pharmaceuticals (Suzhou) Co., Ltd. Antibodies against ror1 and uses thereof
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US7608681B2 (en) 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
US20040071705A1 (en) 2002-06-21 2004-04-15 Dyax Corporation Serum protein-associated target-specific ligands and identification method therefor
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004042072A2 (en) 2002-11-01 2004-05-21 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
PL1877073T3 (pl) 2004-12-01 2014-03-31 The Sec Dep For Health Niecytotoksyczne koniugaty białkowe
EP2535350B1 (en) 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
US10407513B2 (en) 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
WO2011006915A2 (en) 2009-07-16 2011-01-20 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
EP3204415B1 (en) 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
JP2017536341A (ja) * 2014-10-09 2017-12-07 エンクマフ アーゲー 卵巣がんの処置における使用のためのCD3εおよびROR1に対する二特異性抗体
KR20250091329A (ko) * 2015-06-15 2025-06-20 누맙 세러퓨틱스 아게 이종 이량체 다중 특이적 항체 포맷
CA3011419A1 (en) 2016-01-22 2017-07-27 Janssen Biotech, Inc. Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same
AR108034A1 (es) 2016-02-17 2018-07-11 Macrogenics Inc Moléculas de unión a ror1, y métodos de uso de las mismas
US20190233534A1 (en) * 2016-07-14 2019-08-01 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
WO2018224441A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
US12098203B2 (en) * 2017-06-05 2024-09-24 Numab Therapeutics AG Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA
GB201710838D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
EP3459968A1 (en) 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations
KR20220012313A (ko) 2019-05-23 2022-02-03 벨로스바이오 인코포레이티드 항-ror1/항-cd3 이중특이적 결합 분자

Similar Documents

Publication Publication Date Title
JP2024037894A5 (cg-RX-API-DMAC7.html)
CN111278861A (zh) Pd-l1抗体、其抗原结合片段及医药用途
IL276830B2 (en) Anti-claudin 18.2 antibodies and uses thereof
JP2021531005A5 (cg-RX-API-DMAC7.html)
JP2019535254A5 (ja) 抗pd−l1抗体および変異型
JP2019110906A5 (cg-RX-API-DMAC7.html)
RU2019116661A (ru) Антитела против pd-l1 и их варианты
JP2014530215A5 (cg-RX-API-DMAC7.html)
JP2022542165A5 (cg-RX-API-DMAC7.html)
JP2021511811A5 (cg-RX-API-DMAC7.html)
JP2018503380A5 (cg-RX-API-DMAC7.html)
JP2017149720A5 (cg-RX-API-DMAC7.html)
JP2015535828A5 (cg-RX-API-DMAC7.html)
JP2017535257A5 (cg-RX-API-DMAC7.html)
JP2019531764A5 (cg-RX-API-DMAC7.html)
JP2010535713A5 (cg-RX-API-DMAC7.html)
RU2009115363A (ru) Антагонисты рецепторов для лечения метастатического рака
JP2021528047A5 (cg-RX-API-DMAC7.html)
JP2011518546A5 (cg-RX-API-DMAC7.html)
JP2013527762A5 (cg-RX-API-DMAC7.html)
JP2020501598A5 (cg-RX-API-DMAC7.html)
JP2017521054A5 (cg-RX-API-DMAC7.html)
JP2020505075A5 (cg-RX-API-DMAC7.html)
JP2024540148A5 (cg-RX-API-DMAC7.html)
JP2021512652A5 (cg-RX-API-DMAC7.html)